Loading
Life sciences · Journal article
Experimental Biology and Medicine · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Cancer remains a leading cause of mortality worldwide. The success of plant-derived chemotherapeutic agents, such as paclitaxel and vinblastine, underscores the significant potential of plant-derived natural products (PDNPs) in oncology. Despite this success, the poor solubility, metabolic instability, and nonspecific distribution of many PDNPs pose a fundamental barrier to their full clinical potential. Plant-derived extracellular vesicles (PDEVs) have garnered considerable attention as biocompatible nanocarriers, and numerous reviews have examined their biological activities and delivery applications. However, few have systematically addressed their synergistic combination with PDNPs in cancer therapy. This review distinguishes itself by centering on the synergistic interplay between PDNPs and PDEVs as an integrated therapeutic strategy. Specifically, we examine: (1) how PDEVs enhance the bioavailability and anticancer efficacy of PDNPs by improving their solubility, stability, and targeted delivery, and (2) how the intrinsic antitumor activity of PDEVs complements that of PDNPs to achieve enhanced therapeutic efficacy and reduced systemic toxicity compared with either agent alone. By integrating current evidence on the combined use of PDNPs and PDEVs, this review aims to enhance the field’s understanding of the progress made by PDNPs and PDEVs in cancer therapy, clarify their mechanisms of action, and identify the critical challenges facing the current research stage.